Understanding: Diversity In Medical Cannabis

Are we offering more meaningful options, or just more names?

Over the past few years the UK medical cannabis market has expanded rapidly. New cultivars appear on pharmacy menus almost monthly, often accompanied by distinctive names and impressive cannabinoid numbers. On the surface, this can feel like meaningful diversity. But the real question is more complicated.

Are we genuinely expanding the range of therapeutic options available to patients, or simply introducing more variations of the same underlying genetic families?

Understanding this distinction matters, because diversity is not about novelty. It is about suitability.

A growing catalogue

Today, UK patients have access to 200+ cannabis flower products across multiple producers and pharmacies. Some resources catalogue a wide array of cultivars, with products ranging across different THC and CBD (as well as other cannabinoids) ratios and formats.

Some are well-known global cultivars such as Gelato, while others are newer hybrids derived from modern breeding programmes. For example, Gelato itself is a hybrid cultivar known for dense buds and strong visual appeal, characteristics inherited from earlier breeding lines.

On paper, this breadth suggests variety. But when you begin to examine lineage, patterns quickly emerge.

The family tree problem

Modern cannabis breeding is highly iterative. Cultivars are crossed, selected, stabilised, and crossed again. Over time, a relatively small group of influential parents appears repeatedly in the ancestry of many modern strains.

Without speculating beyond verified data, a few broad trends are easy to observe across international breeding:

• Many contemporary hybrids trace lineage to a limited number of historic cultivars.
• Popular genetics are repeatedly reworked to produce new phenotypes.
• The naming of cultivars often evolves faster than the underlying genetics.

This is not a flaw in the system. It is simply how plant breeding works.

Breeders identify traits that perform well; structure, terpene expression, yield, resilience etc and they build upon them. The result is a large catalogue of cultivars that may share deeper genetic roots while expressing different combinations of characteristics.

For patients, the implications are important.

A long menu does not automatically mean a diverse therapeutic toolkit.

Why diversity still matters

Despite shared lineage, cannabis cultivars can express dramatically different characteristics.

Small changes in genetics, combined with cultivation environment, harvesting decisions and post-harvest handling, can influence:

• cannabinoid balance
• terpene composition
• onset and duration of effects
• perceived intensity

This means two cultivars that appear related on paper can feel quite different to a patient.

And that is precisely why diversity matters.

The endocannabinoid system varies from person to person. What brings relief to one patient may feel ineffective or uncomfortable to another. No single cultivar, however popular, can meet every patient’s needs.

Diversity allows clinicians and patients to explore compatibility.

Diversity is not just about strains

Another common misconception is that diversity only refers to cultivars. In reality, it also includes formats.

Flower, oils, capsules, and other delivery systems each interact with the body differently. The same cannabinoid profile can produce very different experiences depending on how it is delivered, because the route of administration changes how cannabinoids are absorbed, metabolised and distributed in the body.

For example:

• Inhaled formats often provide faster onset
  • When cannabinoids are inhaled, compounds such as THC enter the bloodstream through the lungs and can reach peak plasma concentrations within minutes.
• Oral formulations can offer longer duration
  • By contrast, orally ingested cannabinoids are absorbed more slowly through the digestive system and undergo first-pass metabolism in the liver. Effects typically begin after around 30–90 minutes and can last several hours longer than inhaled forms.
• Balanced THC/CBD products may suit patients sensitive to higher THC concentrations
  • Clinical research has also shown that different cannabinoid ratios can influence tolerability and therapeutic response, meaning formulations with both THC and CBD may be preferred by some patients who are sensitive to higher THC exposure.

True therapeutic diversity therefore sits at the intersection of genetics, chemistry, and format.

A market with twenty similar THC flowers is not necessarily more diverse than one with ten carefully differentiated products across multiple delivery methods.

Sources:

• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids (Clinical Pharmacokinetics)
• Lucas et al. The pharmacokinetics and pharmacodynamics of cannabinoids (2018 review)
• Vandrey et al. Pharmacokinetic profile of oral cannabis in humans (2017)

Millar et al. Systematic review of cannabidiol pharmacokinetics (Frontiers in Pharmacology)

The challenge of meaningful choice

As markets mature, there is a natural temptation to equate progress with quantity. More cultivars, more names, more SKUs.

In adult-use markets, this approach can make sense. Variety is often part of the experience. New names, new crosses, and limited releases all contribute to a culture of exploration and novelty.

But medical markets operate under a different logic.

Patients and clinicians rarely benefit from noise. What they need is clarity; a set of options that are meaningfully differentiated and consistently available.

Meaningful diversity is therefore not about filling shelves. It is about expanding the range of distinct therapeutic profiles available.

That might mean:

• a cultivar with a genuinely different terpene expression
• a cannabinoid balance that fills an existing gap
• a format that offers more consistent dosing

In other words, diversity in a medical context should increase clinical usefulness, not simply catalogue size.

A young market finding its shape

The UK medical cannabis sector is still in its early stages. New cultivars will continue to appear as producers refine their breeding programmes and supply chains.

This process is healthy. It reflects experimentation, learning, and gradual market development.

But alongside this growth, it is worth maintaining a simple perspective.

Not every new name represents a new category of therapeutic experience. Sometimes it represents a subtle variation within an existing genetic lineage.

Understanding that difference helps patients, clinicians and producers alike focus on what actually matters: compatibility.

Because the goal of diversity is not to create an impressive looking menu, it is to improve the odds that every patient can find something that works for them.